VKH
VYGR icon

Virtu KCG Holdings’s Voyager Therapeutics VYGR Stock Holding History

Virtu KCG Holdings’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,995
Closed -$132K – 3837
2016
Q3 		$132K Buy
+10,995
New +$149K ﹤0.01% 2547

Other funds holding VYGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Virtu KCG Holdings's VYGR Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Voyager Therapeutics (VYGR) in Q4 2016, closing a stake of 10,995 shares — an estimated $132K sold.

Virtu KCG Holdings first reported a position in VYGR in Q3 2016 and held it in 1 quarter. The position peaked at $132K in Q3 2016. 56 funds tracked by Wall St. Rank hold VYGR as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Voyager Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 10,995 Voyager Therapeutics shares in Q4 2016, an estimated $132K.
  • Virtu KCG Holdings first reported a position in Voyager Therapeutics in Q3 2016 and held it in 1 quarter.
  • Virtu KCG Holdings's Voyager Therapeutics position peaked at $132K in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.